INTRODUCTION: Visfatin is a recently identified adipokine with numerous metabolic and immunoregulatory properties that has been implicated in the regulation of the white adipose tissue (WAT) and significant changes in visfatin levels were reported during pregnancy. The aim of the study was to investigate dynamics of visfatin levels in maternal serum and human breast milk during a 180-d period after the delivery. MATERIALS AND METHODS: : Breast milk and venous blood samples were obtained from 24 healthy lactating women with uncomplicated, physiological pregnancy and appropriate-for-gestational age neonates and serum-milk sample duos were collected at the time of birth, at the 1-3, 12-14, 28-30, 88-90 and 178-180 postpartum. RESULTS: Our study demonstrates that (1) visfatin is abundantly secreted into breast milk in humans, reaching approx. 100× higher concentrations compared to maternal serum; (2) visfatin concentrations in maternal serum show significant variations after the delivery and (3) visfatin concentration in colostrum could be used for prediction of the subsequent weight development (less/more severe weight loss during first 3 days after the birth) of the infant. DISCUSSION: Our data suggest that visfatin could play an important role in regulation of adiposity of the infant after the birth.

Department of Pathological Physiology Masaryk University Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc13001017

003      

CZ-PrNML

005      

20170411115905.0

007      

ta

008      

130108s2012 ie f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.diabres.2011.06.009 $2 doi

035    __

$a (PubMed)21741723

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ie

100    1_

$a Bienertová-Vašků, Julie $u Department of Pathological Physiology, Masaryk University, Brno, Czech Republic. jbienert@med.muni.cz

245    10

$a Visfatin is secreted into the breast milk and is correlated with weight changes of the infant after the birth / $c J. Bienertová-Vašků, P. Bienert, F. Zlámal, J. Tomandl, M. Tomandlová, Z. Dostálová, A. Vašků,

520    9_

$a INTRODUCTION: Visfatin is a recently identified adipokine with numerous metabolic and immunoregulatory properties that has been implicated in the regulation of the white adipose tissue (WAT) and significant changes in visfatin levels were reported during pregnancy. The aim of the study was to investigate dynamics of visfatin levels in maternal serum and human breast milk during a 180-d period after the delivery. MATERIALS AND METHODS: : Breast milk and venous blood samples were obtained from 24 healthy lactating women with uncomplicated, physiological pregnancy and appropriate-for-gestational age neonates and serum-milk sample duos were collected at the time of birth, at the 1-3, 12-14, 28-30, 88-90 and 178-180 postpartum. RESULTS: Our study demonstrates that (1) visfatin is abundantly secreted into breast milk in humans, reaching approx. 100× higher concentrations compared to maternal serum; (2) visfatin concentrations in maternal serum show significant variations after the delivery and (3) visfatin concentration in colostrum could be used for prediction of the subsequent weight development (less/more severe weight loss during first 3 days after the birth) of the infant. DISCUSSION: Our data suggest that visfatin could play an important role in regulation of adiposity of the infant after the birth.

650    _2

$a bílá tuková tkáň $x účinky léků $x metabolismus $7 D052436

650    _2

$a dospělí $7 D000328

650    _2

$a analýza rozptylu $7 D000704

650    _2

$a porodní hmotnost $x účinky léků $x fyziologie $7 D001724

650    _2

$a index tělesné hmotnosti $7 D015992

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a kojenec $7 D007223

650    _2

$a novorozenec $7 D007231

650    _2

$a longitudinální studie $7 D008137

650    _2

$a mateřské mléko $x účinky léků $x metabolismus $7 D008895

650    _2

$a nikotinamidfosforibosyltransferasa $x metabolismus $x sekrece $7 D054409

650    _2

$a těhotenství $7 D011247

650    _2

$a průzkumy a dotazníky $7 D011795

650    _2

$a časové faktory $7 D013997

650    _2

$a hmotnostní přírůstek $x účinky léků $x fyziologie $7 D015430

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Bienert, P

700    1_

$a Zlámal, F

700    1_

$a Tomandl, J

700    1_

$a Tomandlová, M

700    1_

$a Dostálová, Zuzana, $d 1978- $7 xx0075782

700    1_

$a Vašků, A

773    0_

$w MED00001385 $t Diabetes research and clinical practice $x 1872-8227 $g Roč. 96, č. 3 (2012), s. 355-361

856    41

$u https://pubmed.ncbi.nlm.nih.gov/21741723 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20130108 $b ABA008

991    __

$a 20170411120204 $b ABA008

999    __

$a ok $b bmc $g 963799 $s 799181

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2012 $b 96 $c 3 $d 355-361 $i 1872-8227 $m Diabetes research and clinical practice $n Diabetes Res Clin Pract $x MED00001385

LZP    __

$a Pubmed-20130108